Journal Article Summary

The article investigates the effectiveness of cetirizine, an antihistamine, in managing flu-like syndrome (FLS) in patients with relapsing-remitting multiple sclerosis (RRMS) undergoing treatment with interferon beta (IFNβ). FLS is a common side effect of IFNβ therapy, affecting about 75% of patients, and can lead to reduced adherence to treatment and early discontinuation. Understanding and addressing this issue is crucial, as maintaining treatment adherence is linked to better health outcomes in MS patients.

In this pilot study, 45 patients with RRMS who experienced FLS despite standard treatment were randomly assigned to receive either cetirizine or a placebo for four weeks, followed by a switch to the other treatment for another four weeks. The primary measure of effectiveness was the change in FLS severity, assessed using a visual analog scale. The results showed no significant difference in FLS severity between the cetirizine and placebo groups, indicating that cetirizine did not provide additional benefits over standard care.

The study has several limitations, including a small sample size and the variability in FLS severity among patients. Additionally, the study did not measure the levels of interleukin-6 (IL-6), a cytokine thought to be involved in FLS, which could have provided insights into the treatment's effectiveness. Patients should discuss their experiences with FLS and treatment options with their healthcare providers, as managing these symptoms is essential for maintaining adherence to IFNβ therapy and overall health in RRMS.

Medication Safety Note

This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.

Article Cited

  1. Landi Doriana, Albanese Maria, Buttari Fabio, Monteleone Fabrizia, Boffa Laura, Rossi Silvia, Motta Caterina, Puma Elisa, et al.. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. PLoS ONE 2017. DOI: 10.1371/journal.pone.0165415. PMID: 28686675. PMCID: PMC5501388.

Featured Pill Pals Product

Pill Pals® is THE Express Pharmacy. Our Nationwide Pharmacy Network was created with the mission of helping you make SENSE of your meds™. As a Pharmacy Benefits Management organization, Pill Pals® gives patients the best cash prices on all meds. Pill Pals® is part of The Health Pals® Company (Health Pals®, Med Pals®, Skin Pals® etc), a vertically integrated Healthcare System that provides cost effective Medical and Pharmacy services to Employers, Patients, and more. For more information, please email [email protected]